Practice Alert

Screening for hepatitis B: Where the CDC and USPSTF diverge

Author and Disclosure Information

 

References

How CDC and USPSTF guidance on HBV screening differs

The CDC and USPSTF recommendations for HBV screening differ in 3 aspects: whom to screen, whom to classify as at high risk for HBV infection, and what tests to use for screening.

Who should be screened?

The USPSTF recommends screening adults and adolescents who are at high risk for HBV. The CDC recommends screening all adults at least once. Both entities agree that those who are at increased risk should be screened periodically, although the optimal frequency has not been established. The USPSTF does not recommend against screening for the general population, so universal screening (as advocated by the CDC) is not in direct conflict with the USPSTF’s recommendations.

Who is at increased risk for HBV infection?

The CDC and the USPSTF differ slightly on the factors they consider to constitute increased risk for HBV infection. These are listed in ­TABLE 1.1,2

Who’s at heightened risk for hepatitis B infection?A CDC vs USPSTF comparison

The CDC lists 6 categories that the ­USPSTF does not mention. However, 4 of these categories are mentioned indirectly in the USPSTF evidence report that accompanies the recommendations, via statements that certain settings have high proportions of people at risk for HBV infection: sexually transmitted infection clinics; HIV testing and treatment centers; health care settings that target services toward people who inject drugs and men who have sex with men; correctional facilities; hemodialysis facilities; and institutions and nonresidential daycare centers for developmentally disabled persons. People who are served at most of these facilities are also at risk for hepatitis C virus infection.

Three categories are listed by the CDC and not by the USPSTF, in either the recommendation or evidence report. These include a history of multiple sex partners; elevated ALT or aspartate aminotransferase levels of unknown origin; and patient request for testing (because they may not want to reveal risk factors).

Continue to: What test(s) should be ordered?

Pages

Recommended Reading

FDA panel backs new COVID booster focusing only on variants
Federal Practitioner
FDA warns of tattoo ink tied to dangerous infections
Federal Practitioner
Bordetella parapertussis reemerges as a cause of respiratory illness in children
Federal Practitioner
New tool uses nanotechnology to speed up diagnostic testing of infectious disease
Federal Practitioner
Proteomics reveals potential targets for drug-resistant TB
Federal Practitioner
Severe strep infections rebound after pandemic lull
Federal Practitioner
Comorbid respiratory disease key predictor of NTM-PD
Federal Practitioner
Nearly one in five in U.S. still hadn’t gotten COVID by end of 2022
Federal Practitioner
Long COVID and vaccines: Separating facts from falsehoods
Federal Practitioner
Pneumococcal vaccine label adds injection-site risk
Federal Practitioner